Exscientia has advanced a drug candidate for Alzheimer's disease into human testing, the third clinical-stage project for the UK specialist in artificial intelligence (AI) based drug discov
Exscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) last year, and now says it has started testing of the first AI candidate for
There's a new kid on the block among companies using artificial intelligence in drug discovery, after 1910 Genetics launched today with $26 million in financing.
Gain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery platform and pipeline of drugs for diseases associated with prot
New biotech Antiverse has raised seed funding of £1.4 million ($2 million) to develop its artificial intelligence-based platform for discovering therapeutic antibodies.
Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkins
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.